The Surgical Management of Intracranial Metastasis Secondary to Follicular Cell-Derived Thyroid Carcinoma.

IF 2 3区医学 Q3 ONCOLOGY

Journal of Surgical Oncology Pub Date : 2024-09-27 DOI:10.1002/jso.27883

Victoria Harries, Alana Eagan, R Michael Tuttle, Ashok R Shaha, Richard J Wong, Jatin P Shah, Snehal G Patel, Cameron Brennan, Ian Ganly

{"title":"The Surgical Management of Intracranial Metastasis Secondary to Follicular Cell-Derived Thyroid Carcinoma.","authors":"Victoria Harries, Alana Eagan, R Michael Tuttle, Ashok R Shaha, Richard J Wong, Jatin P Shah, Snehal G Patel, Cameron Brennan, Ian Ganly","doi":"10.1002/jso.27883","DOIUrl":null,"url":null,"abstract":"Background: Intracranial metastases (ICM) from follicular cell-derived thyroid carcinoma (FCDTC) are rare and are associated with a poor prognosis. The objective of this study is to report our experience in the surgical management of patients with ICM secondary to FCDTC.Methods: Patients with FCDTC who underwent surgical resection of an ICM were identified at our institution from 1998 to 2018.Results: Thirty-two patients were included in this study. Nineteen patients (59%) had involvement of the brain parenchyma only, 8 (25%) had a dural-based metastasis, 3 (9%) had a calvarial metastasis with dural extension, and 2 (6%) had a skull base metastasis with dural extension. In patients who had an R0-1 resection, the estimated lesional control at the site of resection was 91% at 3 years. However, overall ICM control was 37% at 3 years due to the progression of other ICM lesions. The 1-year disease-specific survival (DSS) was 87% and 5-year DSS was 37%.Conclusions: ICM management in FCDTC is based on the size, number, and location of metastatic lesions. Complete resection of ICM may provide lesional control at the site of resection, however, DSS is poor due to the presence of other ICMs and metastases at multiple distant sites.","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jso.27883","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Intracranial metastases (ICM) from follicular cell-derived thyroid carcinoma (FCDTC) are rare and are associated with a poor prognosis. The objective of this study is to report our experience in the surgical management of patients with ICM secondary to FCDTC.

Methods: Patients with FCDTC who underwent surgical resection of an ICM were identified at our institution from 1998 to 2018.

Results: Thirty-two patients were included in this study. Nineteen patients (59%) had involvement of the brain parenchyma only, 8 (25%) had a dural-based metastasis, 3 (9%) had a calvarial metastasis with dural extension, and 2 (6%) had a skull base metastasis with dural extension. In patients who had an R0-1 resection, the estimated lesional control at the site of resection was 91% at 3 years. However, overall ICM control was 37% at 3 years due to the progression of other ICM lesions. The 1-year disease-specific survival (DSS) was 87% and 5-year DSS was 37%.

Conclusions: ICM management in FCDTC is based on the size, number, and location of metastatic lesions. Complete resection of ICM may provide lesional control at the site of resection, however, DSS is poor due to the presence of other ICMs and metastases at multiple distant sites.

查看原文本刊更多论文

继发于滤泡细胞衍生型甲状腺癌的颅内转移的手术治疗。

背景：滤泡细胞源性甲状腺癌（FCDTC）颅内转移（ICM）非常罕见，且预后较差。本研究旨在报告我们对继发于 FCDTC 的 ICM 患者进行手术治疗的经验：方法：1998 年至 2018 年期间，我院对接受 ICM 手术切除的 FCDTC 患者进行了鉴定：本研究共纳入 32 例患者。19例患者（59%）仅累及脑实质，8例（25%）有硬脑膜转移，3例（9%）有颅骨转移伴硬脑膜扩展，2例（6%）有颅底转移伴硬脑膜扩展。在接受 R0-1 切除术的患者中，估计 3 年后切除部位的病变控制率为 91%。然而，由于其他 ICM 病变的进展，3 年后 ICM 的总体控制率为 37%。1年疾病特异性生存率（DSS）为87%，5年DSS为37%：结论：FCDTC 中的 ICM 治疗取决于转移病灶的大小、数量和位置。完全切除 ICM 可控制切除部位的病变，但由于存在其他 ICM 和多个远处转移灶，DSS 较低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Surgical Oncology 医学-外科

CiteScore

4.70

自引率

4.00%

发文量

367

审稿时长

2 months

期刊介绍： The Journal of Surgical Oncology offers peer-reviewed, original papers in the field of surgical oncology and broadly related surgical sciences, including reports on experimental and laboratory studies. As an international journal, the editors encourage participation from leading surgeons around the world. The JSO is the representative journal for the World Federation of Surgical Oncology Societies. Publishing 16 issues in 2 volumes each year, the journal accepts Research Articles, in-depth Reviews of timely interest, Letters to the Editor, and invited Editorials. Guest Editors from the JSO Editorial Board oversee multiple special Seminars issues each year. These Seminars include multifaceted Reviews on a particular topic or current issue in surgical oncology, which are invited from experts in the field.